Clinical Trials
33 trialsMEN-301
NX Development Corp
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Massachusetts General Hospital
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Massachusetts Eye and Ear Infirmary
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
Rabin Medical Center
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Radiation Therapy Oncology Group
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Massachusetts General Hospital
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
SCRI Development Innovations, LLC
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Wake Forest University Health Sciences
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
SCUSF1202
University of South Florida
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Magnesium and Intraoperative Blood Loss in Meningioma Surgery
Mahidol University
Stereotactic Body Radiotherapy for Spine Tumors
Mercy Research
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Northwestern University
Monthly SOM230C for Recurrent or Progressive Meningioma
Dana-Farber Cancer Institute
Antineoplaston Therapy in Treating Patients With Meningioma
Burzynski Research Institute
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
Proton/Photon Rt - Benign Meningiomas(P92-13)
Massachusetts General Hospital
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
National Cancer Institute (NCI)
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
University of Utah
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
SWOG Cancer Research Network
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
University of Utah
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Duke University